Irinotecan as second-line chemotherapy, after failure to 5FU for metastatic colorectal cancer: Phase III trials;Chimiotherapie par irinotecan en deuxieme ligne de traitement des cancers colorectaux metastatiques: Etudes de phase III

Bulletin du Cancer

Volumn 85, Issue SPEC. ISS. DEC., 1998, Pages 38-42

  Mitry, Emmanuel ^a   Ducreux, Michel ^b   Rougier, Philippe ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Advance colorectal cancer; Irinotecan; Prospective study

Indexed keywords

FLUOROURACIL; IRINOTECAN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; TUMOR PROTEIN;

CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; TREATMENT FAILURE; ADENOCARCINOMA; AGED; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SALVAGE THERAPY; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032412297     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993 ; 29A : 2077-9.
2. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer : a randomized trial. J Clin Oncol 1992 ; 10 : 904-11.
3. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993 ; 306 : 752-5.
4. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 1994 ; 73 : 556-62.
5. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997 ; 15 : 251-60.
6. Van Custem E, Rougier P, Droz JP, Marty M, Bleiberg H. Clinical benefit of irinotecan (CPT11) in metastatic colorectal cancer resistant to 5FU. Proc Am Soc Clin Oncol 1997 ; 16 : 268a.
7. Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluoro-uracil failure for patients with metastatic colorectal cancer. Lancet 1998 ; 352 : 1413-18.
8. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluoro-uracil by continuous infusion after fluoro-uracil failure in patients with metastatic colorectal cancer. Lancet 1998 ; 352 : 1407-12.
9. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Étienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study. J Clin Oncol 1997 ; 15 : 808-15.
10. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal cancer. J Clin Oncol 1991 ; 9 : 625-30.
11. Weh HJ, Wilke HJ, Dierlamm J, Klaassen U, Siegmund R, Illiger HJ, et al. Weekly therapy with folinic acid (FA) and high-dose fluorouracil (5FU) 24 hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 1994 ; 5 : 233-7.
12. Rougier P, Ychou M, Seitz JF, Bonnay M, Mignard D, Couteau C, et al. Phase I/II study of CPT-11 in combination with LV5FU2 (de Gramont-Regimen) every 2 weeks for the treatment of colorectal cancer (CRC) after 5FU failure. Eur J Cancer 1997 ; 33 (suppl. 8) : 51-69.
13. Cvitkovic E, Wasserman E, Riofrio M, Goldwasser F, Mignard D, Mahjoubi M, et al. CPT11/oxaliplatin(L-OHP) : thymidylate synthase (TS) independent combination with efficacy in 5FU refractory colorectal cancer (CRC) patients (PTS). Proc Am Soc Clin Oncol 1998 ; 17 : 278a.